New robot-controlled waterjet treatment offers another option for men suffering from enlarged prostate symptoms.

Sentara Northern Virginia Medical Center pilots Aquablation procedure to help men with BPH

Image Aquarect Image Aquarect Image Aquarect

Sentara Northern Virginia Medical Center announced today there is new hope for men who suffer from lower urinary tract symptoms (LUTS) as a result of benign prostatic hyperplasia (BPH), which is a non-cancerous enlargement of the prostate. The new treatment, called Aquablation® therapy, is performed by the AQUABEAM System which uses a robot-controlled waterjet to remove the enlarged prostate tissue. It is the only FDA-cleared minimally invasive treatment for BPH that combines real-time, multi-dimensional imaging with surgical robotics and a heat-free waterjet for targeted, precise and safe removal of prostate tissue, with a reduced risk of sexual side effects.

Urologist John B. Klein, M.D. is one of the first doctors on the East Coast to offer this new treatment.

Until recently, with current BPH treatment options, men have had to choose between significant symptom relief with a high risk of sexual side effects or a lower risk of sexual complications with less symptomatic benefit. For this reason, many men have avoided treatment altogether. Aquablation therapy eliminates the need for men to make the choice between symptom relief and risk. Aquablation therapy with the AQUABEAM System is designed to break the tradeoff in BPH treatment between efficacy and negative side effects, offering significant symptom improvement with a low risk of sexual complications.

“With enlarged prostate or BPH, the symptoms cause fairly abrupt decrease in quality of life, people can’t go to a movie without getting up twice to urinate, they can’t sleep through the night – that’s a big thing. It’s one thing if you get up once and fall back asleep; it’s another if you get up three times and you can’t get back to sleep afterwards or your wife can’t get back to sleep afterward. It’s a real stressful thing,” said Dr. Klein of Potomac Urology, “We believe this therapy may fundamentally transform the way we treat men with BPH.”

BPH is a highly prevalent condition affecting approximately 50 percent of men age 60 or older and 90 percent of men age 85 or older.  In the United States, there are over 12 million men being actively managed for their condition, of which two million have failed medical management and are looking for alternative treatment options.

Those suffering from the uncomfortable symptoms of an enlarged prostate can find out more about Aquablation therapy by contacting Sentara Northern Virginia Medical Center at 703-680-2111.

About the AQUABEAM System
The AQUABEAM System delivers Aquablation therapy and is the world’s first commercially available surgical robot providing autonomous tissue removal for the treatment of BPH. The AQUABEAM System’s commercial access to the U.S. market was supported by the results of the global WATER (Waterjet Ablation Therapy for Endoscopic Resection of prostate tissue) study, a 181-patient, double-blind, randomized clinical trial comparing Aquablation therapy with the AQUABEAM System with Transurethral Resection of the Prostate (TURP) for the treatment of LUTS caused by BPH. When compared to TURP, the surgical gold standard, Aquablation therapy demonstrated TURP-like efficacy outcomes with a superior safety profile including a reduction in sexual side effects by a ratio of four to one. The AQUABEAM System is commercially available in the U.S., Canada, Australia, New Zealand and select European markets.